Alnylam Pharmaceuticals, Inc. (ALNY)

Market Cap	60.84B
Revenue (ttm)	3.21B
Net Income (ttm)	43.57M
Shares Out	132.11M
EPS (ttm)	0.33
PE Ratio	1,396.19
Forward PE	69.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	962,122
Open	449.00
Previous Close	449.16
Day's Range	449.00 - 463.92
52-Week Range	205.87 - 495.55
Beta	0.29
Analysts	Strong Buy
Price Target	483.89 (+5.07%)
Earnings Date	Oct 30, 2025

About ALNY

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2004
• Employees: 2,230
• Stock Exchange: NASDAQ
• Ticker Symbol: ALNY
• Website: https://www.alnylam.com

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Analyst Summary

According to 27 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $483.89, which is an increase of 5.07% from the latest price.

Price Target

$483.89

(5.07% upside)

Analyst Consensus: Strong Buy